TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of an Ethanol/Sodium Citrate Locking Solution to Prevent Hemodialysis Catheter-Related Infections: A Pilot Study
Brief Summary: Currently in Canada, either 4% sodium citrate or heparin 1,000-10,000 U/ml solutions are "locked" into hemodialysis catheters between dialysis sessions to prevent thrombosis. The use of an ethanol/sodium citrate locking solution may have advantages over either of these agents alone. The investigators hypothesize that the 30 % ethanol/4% sodium citrate catheter locking solution is safe and effective in the prevention of catheter-related infections and thrombosis.


Options:
A: Intervention Type: DRUG; Name: taurolidine; Assigned to Arm(s): N/A
B: Arm Label: 30 % ethanol/ 4 % sodium citrate group; Type: EXPERIMENTAL; Interventions: Other: 30 % ethanol / 4% sodium citrate catheter locking solution | Arm Label: Heparin 1000 U/ml; Type: EXPERIMENTAL; Interventions: Drug: Heparin 1000 u / ml | Intervention Type: OTHER; Name: 30 % ethanol / 4% sodium citrate catheter locking solution; Assigned to Arm(s): 30 % ethanol/ 4 % sodium citrate group | Intervention Type: DRUG; Name: Heparin 1000 u / ml; Assigned to Arm(s): Heparin 1000 U/ml
C: Arm Label: AAT-023 (Zuragen Arm); Type: EXPERIMENTAL; Interventions: Device: AAT-023 solution (Zuragen) | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DEVICE; Name: AAT-023 solution (Zuragen); Assigned to Arm(s): AAT-023 (Zuragen Arm) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin
D: Arm Label: lack of drug prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HBPM 2500 UI anti Xa in one subcutaneous injection per day; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Arm Label: warfarine 1mg daily; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Intervention Type: DRUG; Name: warfarine - low molecular heparin; Assigned to Arm(s): HBPM 2500 UI anti Xa in one subcutaneous injection per day, warfarine 1mg daily

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicentre, Prospective, Randomised, 2-arm Study to Assess the Impact of Ferric Carboxymaltose on Exercise Capacity in Chronic Heart Failure Patients With Iron Deficiency
Brief Summary: The purpose of this study is to confirm that treatment with IV ferric carboxymaltose improves exercise capacity, physical functioning and quality of life in patients with iron deficiency and chronic heart failure.


Options:
A: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Oral iron supplement every day for 14 days; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days | Arm Label: Oral iron supplement every second day for 28 days; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days | Intervention Type: DIETARY_SUPPLEMENT; Name: Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days; Assigned to Arm(s): Oral iron supplement every day for 14 days | Intervention Type: DIETARY_SUPPLEMENT; Name: Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days; Assigned to Arm(s): Oral iron supplement every second day for 28 days
C: Arm Label: Single oral iron supplement per day (120 mg); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Single oral iron dose of 120 mg per day for 3 consecutive days | Arm Label: B.i.d. oral iron supplement (2x 60 mg); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days | Intervention Type: DIETARY_SUPPLEMENT; Name: Single oral iron dose of 120 mg per day for 3 consecutive days; Assigned to Arm(s): Single oral iron supplement per day (120 mg) | Intervention Type: DIETARY_SUPPLEMENT; Name: Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days; Assigned to Arm(s): B.i.d. oral iron supplement (2x 60 mg)
D: Arm Label: Ferinject; Type: EXPERIMENTAL; Interventions: Drug: Ferinject | Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline | Intervention Type: DRUG; Name: Ferinject; Assigned to Arm(s): Ferinject | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Computer-based Telephone Counseling Improve Long-term Adherence to Strength Training in Elders With Knee Osteoarthritis (OA)?
Brief Summary: The purpose of this research is to determine whether computer-based telephone counseling will improve adherence to strength training in a population of elders with knee osteoarthritis.


Options:
A: Arm Label: active; Type: ACTIVE_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Intervention Type: DEVICE; Name: Wearable pulsed electromagnetic fields; Assigned to Arm(s): active, placebo
B: Arm Label: Telephone-linked Communication (TLC); Type: EXPERIMENTAL; Interventions: Behavioral: TLC | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: TLC; Assigned to Arm(s): Telephone-linked Communication (TLC)
C: Arm Label: Treatment arm 1; Type: ACTIVE_COMPARATOR; Interventions: Other: magnetotherapy | Arm Label: Treatment arm 2; Type: ACTIVE_COMPARATOR; Interventions: Device: laser auriculotherapy | Arm Label: Treatment arm 3; Type: EXPERIMENTAL; Interventions: Other: magnetotherapy, Device: laser auriculotherapy | Arm Label: Placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: magnetotherapy; Assigned to Arm(s): Treatment arm 1, Treatment arm 3 | Intervention Type: DEVICE; Name: laser auriculotherapy; Assigned to Arm(s): Treatment arm 2, Treatment arm 3 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo arm
D: Arm Label: HIPL Therapy™ group; Type: EXPERIMENTAL; Interventions: Device: High Intensity Physio Light Therapy (HIPL Therapy™), Behavioral: Education, Behavioral: Aerobic Exercise, Behavioral: Resistance Exercise | Arm Label: Placebo Control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Education, Behavioral: Aerobic Exercise, Behavioral: Resistance Exercise, Device: Placebo Physio Light Therapy (HIPL Therapy™) | Intervention Type: DEVICE; Name: High Intensity Physio Light Therapy (HIPL Therapy™); Assigned to Arm(s): HIPL Therapy™ group | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): HIPL Therapy™ group, Placebo Control group | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise; Assigned to Arm(s): HIPL Therapy™ group, Placebo Control group | Intervention Type: BEHAVIORAL; Name: Resistance Exercise; Assigned to Arm(s): HIPL Therapy™ group, Placebo Control group | Intervention Type: DEVICE; Name: Placebo Physio Light Therapy (HIPL Therapy™); Assigned to Arm(s): Placebo Control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)
Brief Summary: The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.


Options:
A: Arm Label: Canagliflozin (JNJ-28431754); Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, 100 mg, Drug: Canagliflozin, 300 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin, 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) | Intervention Type: DRUG; Name: Canagliflozin, 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754)
B: Arm Label: Empagliflozin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo
D: Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)
Brief Summary: The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.


Options:
A: Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin, Drug: glimepiride placebo | Arm Label: glimepiride 1-4 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: linagliptin placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: linagliptin placebo; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: glimepiride placebo; Assigned to Arm(s): linagliptin
C: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
D: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPTImal CArdiac REhabilitation (OPTICARE)Following Acute Coronary Syndromes: A Randomized, Controlled Trial to Investigate the Benefits of an Expanded Educational and Behavioural Intervention Program.
Brief Summary: The objective is to investigate whether in acute coronary syndrome patients the cardiac risk profile will improve with 2 new extended cardiac rehabilitation interventions and if these patients maintain healthier life style habits and a more active life style compared to patients randomized to standard cardiac rehabilitation.


Options:
A: Arm Label: Attention Control Group (AC); Type: ACTIVE_COMPARATOR; Interventions: Other: Mediterranean Diet Recommendations, Other: Physical Activity Recommendations | Arm Label: HV-HIIT; Type: EXPERIMENTAL; Interventions: Other: HIGH VOLUME (HV) Supervised exercise, Other: Mediterranean Diet Recommendations | Arm Label: LV-HIIT; Type: EXPERIMENTAL; Interventions: Other: Mediterranean Diet Recommendations, Other: LOW VOLUME (LW) Supervised exercise | Intervention Type: OTHER; Name: HIGH VOLUME (HV) Supervised exercise; Assigned to Arm(s): HV-HIIT | Intervention Type: OTHER; Name: Mediterranean Diet Recommendations; Assigned to Arm(s): Attention Control Group (AC), HV-HIIT, LV-HIIT | Intervention Type: OTHER; Name: Physical Activity Recommendations; Assigned to Arm(s): Attention Control Group (AC) | Intervention Type: OTHER; Name: LOW VOLUME (LW) Supervised exercise; Assigned to Arm(s): LV-HIIT
B: Arm Label: OPTICARE-A; Type: EXPERIMENTAL; Interventions: Other: rehabilitation+telephonic coaching | Arm Label: OPTICARE-B; Type: ACTIVE_COMPARATOR; Interventions: Other: OPTICARE-B | Arm Label: OPTICARE-C; Type: EXPERIMENTAL; Interventions: Other: OPTICARE-C | Intervention Type: OTHER; Name: rehabilitation+telephonic coaching; Assigned to Arm(s): OPTICARE-A | Intervention Type: OTHER; Name: OPTICARE-B; Assigned to Arm(s): OPTICARE-B | Intervention Type: OTHER; Name: OPTICARE-C; Assigned to Arm(s): OPTICARE-C
C: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training
D: Arm Label: Baduanjin exercise group; Type: EXPERIMENTAL; Interventions: Other: Baduanjin exercise | Arm Label: usual exercise control group; Type: ACTIVE_COMPARATOR; Interventions: Other: aerobic exercise | Intervention Type: OTHER; Name: Baduanjin exercise; Assigned to Arm(s): Baduanjin exercise group | Intervention Type: OTHER; Name: aerobic exercise; Assigned to Arm(s): usual exercise control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: OPTImal CArdiac REhabilitation (OPTICARE)Following Acute Coronary Syndromes: A Randomized, Controlled Trial to Investigate the Benefits of an Expanded Educational and Behavioural Intervention Program.
Brief Summary: The objective is to investigate whether in acute coronary syndrome patients the cardiac risk profile will improve with 2 new extended cardiac rehabilitation interventions and if these patients maintain healthier life style habits and a more active life style compared to patients randomized to standard cardiac rehabilitation.


Options:
A: Arm Label: PATCH Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PATCH intervention | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: PATCH intervention; Assigned to Arm(s): PATCH Intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care
B: Arm Label: OPTICARE-A; Type: EXPERIMENTAL; Interventions: Other: rehabilitation+telephonic coaching | Arm Label: OPTICARE-B; Type: ACTIVE_COMPARATOR; Interventions: Other: OPTICARE-B | Arm Label: OPTICARE-C; Type: EXPERIMENTAL; Interventions: Other: OPTICARE-C | Intervention Type: OTHER; Name: rehabilitation+telephonic coaching; Assigned to Arm(s): OPTICARE-A | Intervention Type: OTHER; Name: OPTICARE-B; Assigned to Arm(s): OPTICARE-B | Intervention Type: OTHER; Name: OPTICARE-C; Assigned to Arm(s): OPTICARE-C
C: Intervention Type: OTHER; Name: Peer Support; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial
Brief Summary: This study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and other organs, blocking these channels might help to prevent the accumulation of iron in these tissues. The study will follow 60 patients with thalassemia major: 30 will receive amlodipine and 30 will serve as controls receiving placebo in a randomized double-blind fashion. Patients will be monitored through one year. Monitoring will occur through the measurement of blood ferritin as well as live and heart T2\* by MRI initially, at 6 and 12 months.


Options:
A: Arm Label: Thalassemia; Type: N/A; Interventions: N/A
B: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)
C: Arm Label: Starch pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amlodipine | Arm Label: Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine, Starch pill
D: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major: a Randomized, Controlled Trial
Brief Summary: This study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and other organs, blocking these channels might help to prevent the accumulation of iron in these tissues. The study will follow 60 patients with thalassemia major: 30 will receive amlodipine and 30 will serve as controls receiving placebo in a randomized double-blind fashion. Patients will be monitored through one year. Monitoring will occur through the measurement of blood ferritin as well as live and heart T2\* by MRI initially, at 6 and 12 months.


Options:
A: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)
B: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine
C: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
D: Arm Label: Starch pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amlodipine | Arm Label: Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine, Starch pill

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level
Brief Summary: The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Despite a wide range of therapeutic options, the treatments are associated with short response duration, thus this condition is largely incurable. This investigational drug may offer less toxicity than standard treatments and have better tumor specific targeting.


Options:
A: Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: Brentuximab vedotin | Intervention Type: DRUG; Name: Brentuximab vedotin; Assigned to Arm(s): Brentuximab vedotin
B: Arm Label: Caelyx; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin hydrochloride | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin hydrochloride; Assigned to Arm(s): Caelyx
C: Arm Label: KW-0761; Type: EXPERIMENTAL; Interventions: Biological: KW-0761 | Arm Label: Vorinostat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vorinostat | Intervention Type: BIOLOGICAL; Name: KW-0761; Assigned to Arm(s): KW-0761 | Intervention Type: DRUG; Name: Vorinostat; Assigned to Arm(s): Vorinostat
D: Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: Brentuximab Vedotin | Arm Label: Methotrexate or Bexarotene; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Bexarotene | Intervention Type: DRUG; Name: Brentuximab Vedotin; Assigned to Arm(s): Brentuximab vedotin | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate or Bexarotene | Intervention Type: DRUG; Name: Bexarotene; Assigned to Arm(s): Methotrexate or Bexarotene

Answer: A